Search hospitals > Pennsylvania > York
Cancer Care Associates of York
Claim this profileYork, Pennsylvania 17403
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Prostate Cancer
73 reported clinical trials
4 medical researchers
Summary
Cancer Care Associates of York is a medical facility located in York, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Cancer Care Associates of York is involved with conducting 73 clinical trials across 129 conditions. There are 4 research doctors associated with this hospital, such as Chanh T. Huynh, Dan Sotirescu, Joseph Kannarkatt, and Ikechukwu I. Akunyili.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
EGFR positive
2Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
Top PIs
Chanh T. HuynhAdams Cancer Center2 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
21 reported clinical trials
38 drugs studied
Dan SotirescuEphrata Cancer Center6 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
11 reported clinical trials
28 drugs studied
Joseph KannarkattWellSpan Medical Oncology and Hematology4 years of reported clinical research
Studies Lung Cancer
Studies Lung Carcinoma
7 reported clinical trials
31 drugs studied
Ikechukwu I. AkunyiliEphrata Cancer Center1 year of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
4 reported clinical trials
9 drugs studied
Clinical Trials running at Cancer Care Associates of York
Lung Cancer
Breast Cancer
Cancer
Non-Small Cell Lung Cancer
Breast cancer
Chronic Lymphocytic Leukemia
Ovarian Cancer
Squamous Cell Carcinoma
Bladder Cancer
Esophageal Cancer
Telisotuzumab Vedotin vs. Docetaxel
for Non-Small Cell Lung Cancer
This trial is testing a new drug called telisotuzumab vedotin to see if it can treat a specific type of lung cancer better than an existing drug. The study focuses on adults whose lung cancer has not responded to previous treatments. The new drug targets and kills cancer cells by attaching to a specific protein on their surface.
Recruiting2 awards Phase 312 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Cancer Care Associates of York?
Cancer Care Associates of York is a medical facility located in York, Pennsylvania. This center is recognized for care of Lung Cancer, Breast Cancer, Cancer, Non-Small Cell Lung Cancer, Prostate Cancer and other specialties. Cancer Care Associates of York is involved with conducting 73 clinical trials across 129 conditions. There are 4 research doctors associated with this hospital, such as Chanh T. Huynh, Dan Sotirescu, Joseph Kannarkatt, and Ikechukwu I. Akunyili.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.